Donor immune cells tested as new weapon against Tough-to-Treat lupus
NCT ID NCT07314567
Summary
This early-stage study is testing a new cell therapy called ACE1831 for people with severe systemic lupus erythematosus (SLE) that has not improved with standard treatments. ACE1831 is made from immune cells (gamma delta T cells) donated by healthy people. The main goals are to see if the treatment is safe and if it can reduce lupus disease activity and improve quality of life for the 22 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEM LUPUS ERYTHEMATOSUS(SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital
Wuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.